22 results match your criteria: "Centre de Recherche Saint-Antoine INSERM UMRs938[Affiliation]"

Minimal Residual Disease in Multiple Myeloma.

Presse Med

December 2024

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. Electronic address:

Minimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies, complete eradication of malignant plasma cells remains challenging. MRD refers to a small number of residual cancer cells that persist after treatment and require sensitive methods like next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for detection.

View Article and Find Full Text PDF
Article Synopsis
  • - Immune effector cell-associated hematotoxicity (ICAHT) is a significant and common side effect following CAR-T-cell therapy, particularly impacting patient recovery and health.
  • - The article discusses three cases where patients experienced severe ICAHT after receiving axicabtagene-ciloleucel (axi-cel) for diffuse large B-cell lymphoma, characterized by an increase in a specific type of lymphocyte in the bone marrow.
  • - Treatment with low-dose steroids successfully resolved the cytopenias (low blood cell counts) without harming the effectiveness of the cancer treatment.
View Article and Find Full Text PDF

An international survey to better understand the current incidence, severity, and management of VOD/SOS.

Bone Marrow Transplant

October 2024

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.

Article Synopsis
  • * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
  • * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
View Article and Find Full Text PDF

A boost for poor graft function.

Blood Adv

September 2024

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique - Hopitaux de Paris, Paris, France.

View Article and Find Full Text PDF

Induction prior to autologous haematopoietic cell transplantation in multiple myeloma.

Br J Haematol

December 2024

Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Centre de Recherche Saint-Antoine INSERM UMRs938, Sorbonne Université, Paris, France.

Induction chemotherapy followed by autologous haematopoietic cell transplantation and post-transplant therapy (including maintenance therapy with or without prior consolidation) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma patients. Over the last years, superiority of quadruplet regimens for induction was established, with the addition of an anti-CD38 monoclonal antibody to triplet regimen including a proteasome inhibitor, an IMiD (thalidomide or lenalidomide) or cyclophosphamide, and dexamethasone. Given quadruplet induction regimens are associated with deep response, including a high-rate of sustained measurable residual disease negativity in a significant proportion of patients, they are now recommended for induction chemotherapy when available.

View Article and Find Full Text PDF

The emerging role of melflufen and peptide-conjugates in multiple myeloma.

Curr Opin Oncol

November 2024

Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Purpose Of Review: The past two decades have witnessed an impressive expansion in the treatment landscape of multiple myeloma, leading to significant improvements in progression-free; as well as overall survival. However, almost all patients still experience multiple relapses during their disease course, with biological and cytogenetic heterogeneity affecting response to subsequent treatments. The purpose of this review is to provide a historical background regarding the role of alkylating agents and an updated data regarding the use of peptide-drug conjugates such as melflufen for patients with multiple myeloma.

View Article and Find Full Text PDF
Article Synopsis
  • Primary mediastinal germ-cell tumors (PMGCTs) represent a small percentage of all germ-cell tumors, notably having a poorer prognosis compared to gonadal tumors, with low overall survival rates especially in cases with metastases.
  • A retrospective study assessed the effectiveness of high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for treating 69 adult male patients with primary mediastinal non-seminoma germ cell tumors (PMNSGCT), primarily using carboplatin/etoposide.
  • Results showed that upfront HDC significantly improved progression-free survival and overall survival rates, with a 2-year overall survival rate of 43.3% for the cohort, while identifying predictors for better
View Article and Find Full Text PDF

A roadmap towards improving outcomes in multiple myeloma.

Blood Cancer J

August 2024

Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Nantes-St Herblain, France.

Multiple myeloma (MM) is a chronic hematologic malignancy that remains incurable, because most patients eventually relapse or become refractory to current treatments. MM is a major health problem, with a globally increasing incidence. While, increase in the choice of MM treatment, including new immunotherapies (bispecific monoclonal antibodies and chimeric antigen receptor (CAR)-T cell therapy), may allow to further improve MM patients' outcomes, some non-therapy-related key issues may represent a pre-requisite towards improving MM outcomes in the next few years.

View Article and Find Full Text PDF

Age-related epithelial defects limit thymic function and regeneration.

Nat Immunol

September 2024

Translational Science and Therapeutics Division, and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.

The thymus is essential for establishing adaptive immunity yet undergoes age-related involution that leads to compromised immune responsiveness. The thymus is also extremely sensitive to acute insult and although capable of regeneration, this capacity declines with age for unknown reasons. We applied single-cell and spatial transcriptomics, lineage-tracing and advanced imaging to define age-related changes in nonhematopoietic stromal cells and discovered the emergence of two atypical thymic epithelial cell (TEC) states.

View Article and Find Full Text PDF
Article Synopsis
  • The European Society for Blood and Marrow Transplantation (EBMT) has established a continental registry over 30 years, currently housing data on over 700,000 patients and 800,000 transplants, which supports various research and benchmarking efforts in hematopoietic cell transplantation.
  • The introduction of CAR-T cell therapies, which could significantly impact blood and marrow transplantation practices, prompted EBMT to create a Cellular Therapy Form that registers CAR-T cell treated patients and collects detailed outcome data.
  • The EBMT Registry received approval from the European Medicines Agency in 2019 and now holds information on more than 9,000 patients treated with CAR-T cells, facilitating analyses and evaluations of these therapies' medical value within different contexts
View Article and Find Full Text PDF

Multiple myeloma.

Nat Rev Dis Primers

June 2024

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.

Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence. It remains incurable because most patients relapse or become refractory to treatments.

View Article and Find Full Text PDF
Article Synopsis
  • - The case discusses a patient with relapsed IgA and lambda free light chain multiple myeloma who was on dialysis and treated with elranatamab, a bispecific antibody.
  • - The treatment was found to be feasible even with the patient's severe kidney impairment, and it did not result in any unexpected side effects.
  • - It highlights the importance of monitoring for infectious risks in patients who are both immunocompromised and have renal issues.
View Article and Find Full Text PDF

Background: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd).

Methods: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression-free survival (PFS) and response rates.

View Article and Find Full Text PDF

Melanoma and microbiota: Current understanding and future directions.

Cancer Cell

January 2024

Gustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée par la Ligue Contre le Cancer, 94800 Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Gustave Roussy, 94805 Villejuif, France. Electronic address:

Article Synopsis
  • Research shows that gut microbiota composition can impact cancer treatment responses, specifically in patients receiving immunotherapy for melanoma.
  • * Various mechanisms by which intestinal bacteria influence tumors are being explored to improve the effectiveness of immune checkpoint inhibitors.
  • * The use of advanced "omics" technologies is helping to understand host-microbe interactions, which may lead to personalized treatments and strategies to modify the microbiota for better cancer outcomes.
View Article and Find Full Text PDF

Background: Failure of gastrointestinal acute graft--host disease (GI-aGvHD) to respond to steroid therapy is associated with limited further therapeutic options. We aimed to assess the safety and efficacy of the first-in-human use of the pooled allogeneic faecal microbiota, MaaT013, for the treatment of steroid-refractory GI-aGvHD.

Methods: This prospective, international, single-arm, phase 2a study reports clinical outcomes from a 24-patient cohort with grade III-IV, steroid refractory GI-aGvHD treated with the pooled allogeneic faecal microbiota MaaT013.

View Article and Find Full Text PDF

Updates in chronic graft-versus-host disease management.

Am J Hematol

October 2023

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.

Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in the understanding of the biological pathways of cGvHD, lead to the development of targeted therapy with novel drugs thereby minimizing the exposure to harmful corticosteroids, preserving function and mobility, preventing disability, and improving quality of life (QoL) and overall survival (OS). Steroid-refractory cGvHD management has recently experienced significant improvement since ibrutinib and ruxolitinib were approved for patients that failed at least one line of treatment and belumosudil for patients that failed two lines.

View Article and Find Full Text PDF

Acute graft-versus-host disease.

Nat Rev Dis Primers

June 2023

Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.

Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major health problem in these patients, and is associated with high morbidity and mortality. Acute GVHD is caused by the recognition and the destruction of the recipient tissues and organs by the donor immune effector cells.

View Article and Find Full Text PDF

Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice.

Lancet Haematol

October 2022

Centre de Recherche Saint-Antoine INSERM UMRs938, Sorbonne Université, AP-HP, Paris, France; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.

The effect of the gut microbiota on patients' outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host disease (GVHD). Furthermore, increasing data also suggest an effect of the gut microbiota on outcome after autologous HCT and CAR T cells.

View Article and Find Full Text PDF